Cincinnati Children’s is an international leader in caring for children with kidney tumors. Our experienced specialists treat patients with newly diagnosed, advanced, rare and relapsed kidney cancers, including:
- Wilms tumor
- Renal cell carcinoma (RCC) including translocation RCC
- Rhabdoid tumors
- Clear cell sarcoma
- Renal angiomyolipoma
- Other rare renal tumors
The medical director of the Kidney Tumor Program is James I. Geller, MD, a pediatric oncologist and an internationally recognized expert in kidney tumor therapy and next-generation anticancer drug development. His work and leadership benefits patients at Cincinnati Children’s and around the world.
A Comprehensive, Team Approach
Our physicians and researchers have dedicated their careers to developing new treatments, improving outcomes and enhancing the quality of life for patients and their families who are dealing with these cancers. They work as a well-coordinated team to offer comprehensive, advanced therapies for children with kidney tumors.
The team includes pediatric cancer specialists, surgeons, radiologists and radiation oncologists, among others. Together these experts provide an extensive evaluation and develop a personalized treatment plan that is based on their clinical experience and the most up-to-date research. The team continues to collaborate throughout the child’s course of treatment and provides referring physicians with regular updates to ensure coordinated care.
When a child’s kidney tumor does not respond to standard therapy or has returned after therapy, we look to other options, including experimental protocols, hematopoietic stem cell transplantation and immunotherapies. Many of our advanced treatments are available only at Cincinnati Children’s, which means our patients may have early access to new anticancer therapies, often years before these therapies become widely available. Other advanced therapies are available through our collaboration in national and international research studies.
Cincinnati Children’s physicians have leadership positions with the Children’s Oncology Group and other national research organizations, which strengthens our link to the latest clinical research opportunities. They lead national and international clinical research studies, host scientific meetings for cancer specialists and sponsor conferences to support and educate families who are dealing with kidney cancer.